INTRODUCTION
============

Although all different types of human cells share the same genome, their gene expression is spatially and temporally distinct. Establishing a tissue-specific transcriptional program during development is required for the unique function of each tissue. Enhancers are key regulatory elements that control this process. They consist of short DNA regions, usually located far from gene promoters, can be occupied by co-activators and other transcription factors, and function as *cis*-regulatory elements. Epigenetic modifications such as DNA methylation ([@b27-molce-40-3-169]) and histone modification can regulate enhancers ([@b27-molce-40-3-169]; [@b56-molce-40-3-169]). The current advances in high-throughput sequencing allow us to explore the relationship between enhancer activity and epigenetic changes at enhancer regions in the mammalian genome. With these powerful technologies, it is possible to distinguish between active and inactive enhancers, based on histone modifications such as H3K4me1 and H3K27ac ([@b9-molce-40-3-169]). Moreover, the concept of super-enhancers, comprising multiple individual enhancers within a certain region, has been introduced to describe influential regulatory elements that control tissue-specific transcription ([@b13-molce-40-3-169]; [@b23-molce-40-3-169]; [@b58-molce-40-3-169]; [@b64-molce-40-3-169]). Each individual constituent enhancer of the super-enhancer binds tissue-enriched and lineage-specific transcription factors. For example, in the mammary epithelium, mammary-specific super-enhancers were identified with mammary-enriched transcription factors, such as signal transducer and activator of transcription 5 (STAT5), glucocorticoid receptor (GR), E74 like ETS transcription factor 5 (ELF5), and nuclear factor I B (NFIB), and the active enhancer marker, H3K27ac ([@b55-molce-40-3-169]). Genes associated with mammary-specific super-enhancers were significantly expressed as these super-enhancers were progressively assembled during pregnancy. Furthermore, recent studies have shown that enhancer RNAs (eRNAs) are synthesized at super-enhancer regions ([@b47-molce-40-3-169]; [@b53-molce-40-3-169]). Their function is still not clear, but they are involved in chromatin loop formation for promoter-enhancer interactions ([@b5-molce-40-3-169]). Functional studies of these regulatory elements can help us understand diseases such as cancer, since pathogenic super-enhancers and aberrant eRNA regulation have been identified in tumorigenesis. Herein, we describe recent advances in our understanding of enhancer function during development and disease.

UNDERSTANDING THE MECHANISMS OF TISSUE-SPECIFIC TRANSCRIPTION CONTROL BY ENHANCERS
==================================================================================

Although the role of individual enhancers in cell-type specific gene expression has been studied for a long time, it is only recently that genome-wide analysis has allowed the identification of all enhancers in the mammalian genome. This was achieved by using various histone markers that recognize enhancer regions, as well as the development of whole-genome sequencing techniques ([@b16-molce-40-3-169]; [@b21-molce-40-3-169]; [@b56-molce-40-3-169]). Enhancers are mainly enriched with H3K4me1 and H3K27ac, and do not contain H3K4me3 as a promoter marker, but H3K27ac-enriched enhancers in the active state can be distinguished from poised enhancers occupied with H3K4me1 only ([Fig. 1](#f1-molce-40-3-169){ref-type="fig"}). Poised enhancers are not yet functionally active; however, enrichment in the H3K27ac marker could be observed since they are active to regulate target gene expression. Global analyses by ChIP-seq to detect lineage-specific transcription factors and histone modification markers identified enhancer clusters known as super-enhancers, which are located close to each other in the genome ([Fig. 1](#f1-molce-40-3-169){ref-type="fig"}) ([@b6-molce-40-3-169]; [@b19-molce-40-3-169]; [@b28-molce-40-3-169]; [@b32-molce-40-3-169]; [@b37-molce-40-3-169]; [@b39-molce-40-3-169]; [@b44-molce-40-3-169]; [@b55-molce-40-3-169]; [@b60-molce-40-3-169]; [@b64-molce-40-3-169]). Super-enhancers contain multiple hotspots co-occupied by lineage-specific transcription factors and mediators within a certain region, which typically spans tens of kilobases covered with extended histone modification markers of active enhancers. Therefore, H3K27ac and MED1, lineage-specific factors, are commonly used to identify tissue-specific super-enhancers; combinations of transcription factors and H3K27ac are also used for advanced analysis.

Super-enhancers control tissue-specific gene regulation in mouse stem cells, hair follicle stem cells, macrophages, adipocytes, and mammary epithelium ([@b1-molce-40-3-169]; [@b13-molce-40-3-169]; [@b55-molce-40-3-169]; [@b58-molce-40-3-169]; [@b64-molce-40-3-169]). Several key features enable super-enhancers to regulate tissue-specific gene expression. First, genes associated with super-enhancers are expressed at higher levels than genes associated with typical enhancers, which are single enhancer regions controlling target gene expression. For example, in mouse embryonic stem cells, super-enhancers were found to regulate the key regulatory transcription factors Oct4, Sox2, and Nanog, which were ranked based on MED1 signals ([@b64-molce-40-3-169]). The expression of genes associated with super-enhancers such as *Klf4* and *Esrrb*, which play important roles in cell identity, was significantly higher than that of typical enhancer-associated genes in mouse embryonic stem cells. Similar findings were observed in human stem cells, T cells, and chondrocytes ([@b23-molce-40-3-169]; [@b38-molce-40-3-169]; [@b45-molce-40-3-169]; [@b61-molce-40-3-169]). Moreover, comparison analysis of various tissues showed that super-enhancer-associated genes are highly expressed in a tissue-specific manner. This suggests that super-enhancers act more powerfully on tissue-specific gene expression compared to typical enhancers. Second, super-enhancers are sensitive to environmental changes. The establishment of super-enhancers was shown to be affected by environmental conditions, such as hormones during development in hair follicle stem cells, macrophages and mammary gland ([@b1-molce-40-3-169]; [@b13-molce-40-3-169]; [@b55-molce-40-3-169]). Additionally, super-enhancers were dynamically remodeled by the microenvironment in the wound-repair of hair follicle stem cells, and mammary-specific super-enhancers were progressively assembled during pregnancy when prolactin secretion was increased. In addition, some specific enhancers were immediately switched off when prolactin secretion was reduced ([@b65-molce-40-3-169]), suggesting that super-enhancers are sensitive to perturbations. Finally, individual enhancers consisting of super-enhancers have their own unique functions. Loss of function studies using genome editing tools such as CRISPR/Cas9 revealed the biological functions of each enhancer in a super-enhancer ([@b23-molce-40-3-169]; [@b55-molce-40-3-169]). One of these acts as an epicentric enhancer of a super-enhancer and differs in reactivity in the presence of different transcription factors, affecting the expression of the target gene more strongly ([@b1-molce-40-3-169]; [@b55-molce-40-3-169]). This suggests that super-enhancers, which are formed in a dense form of enhancers with different functions, play important roles in regulating tissue-specific gene regulation.

eRNA AS A SPECIFIC TRANSCRIPTIONAL REGULATOR
============================================

Determination of the molecular mechanism of long noncoding RNA ([@b41-molce-40-3-169]), identification of enhancer RNA (eRNA), and bi-directionally transcribed RNA in enhancer regions ([@b4-molce-40-3-169]; [@b26-molce-40-3-169]; [@b30-molce-40-3-169]; [@b43-molce-40-3-169]), raised questions regarding enhancer establishment, enhancer target-gene regulation, and chromosome looping structure ([@b7-molce-40-3-169]; [@b25-molce-40-3-169]; [@b26-molce-40-3-169]; [@b34-molce-40-3-169]; [@b35-molce-40-3-169]; [@b42-molce-40-3-169]; [@b49-molce-40-3-169]; [@b52-molce-40-3-169]; [@b54-molce-40-3-169]; [@b66-molce-40-3-169]). Global run-on sequencing (GRO-seq) and total RNA-seq are typically applied to identify global eRNAs in the whole genome. Although eRNA is not essential for all enhancers, it affects the regulation of active-enhancer transcription for gene expression ([@b7-molce-40-3-169]; [@b26-molce-40-3-169]). Moreover, it was previously shown that eRNA affects cell-type-specific transcriptional regulation ([@b42-molce-40-3-169]; [@b66-molce-40-3-169]). eRNA is thought to function in enhancer--promoter interactions directly or indirectly to regulate gene expression by transcription pre-initiation complexes RNA pol II, DNA- and RNA-binding transcription factor, or co-factor of DNA- and RNA-binding transcription factor ([Fig. 1](#f1-molce-40-3-169){ref-type="fig"}) ([@b3-molce-40-3-169]; [@b5-molce-40-3-169]; [@b36-molce-40-3-169]). The formation of genomic looping structures, where enhancers interact with promoters, require an eRNA, mediator, and cohesion ([Fig. 1](#f1-molce-40-3-169){ref-type="fig"}) ([@b54-molce-40-3-169]). However, it has recently been reported that eRNA could be a byproduct of the co-occupation of RNA PolII driven by enhancer-promoter looping ([@b29-molce-40-3-169]). The function of eRNA during chromatin looping is still unknown, and further studies on the topic are required.

A previous study reported a correlation between super-enhancers and eRNA, which also coordinated collective transcription factor binding ([@b15-molce-40-3-169]). Even though not all eRNAs were expressed at super-enhancer regions, both super-enhancers and eRNA were affected by genomic damage ([@b51-molce-40-3-169]). Genomic instability can influence the super-enhancer establishment and eRNA expression and as a result, it could affect gene expression. In B cells, many super-enhancers contained activation-induced cytidine deaminase (AID) sequences, even for non-AID target genes. Consequently, AID-induced damage of enhancer regions could affect B cell function. Additionally, it could control chromatin looping by damaging regions involved in promoter-enhancer interactions ([@b51-molce-40-3-169]). A correlation between loss or gain of super-enhancer formation and eRNA expression was clearly observed ([@b15-molce-40-3-169]; [@b53-molce-40-3-169]). Hah et al. ([@b15-molce-40-3-169]) observed that during toll-like receptor 4 (TLR4) signaling in macrophages, \~93% of intergenic super-enhancers were associated with eRNAs, whereas only \~30% of intergenic typical enhancers were associated with eRNAs, suggesting a correlation between super-enhancer formation and eRNA transcription. Accordingly, in those intergenic super-enhancer regions, tissue-specific transcription factor binding and gene expression were much higher. It is possible that eRNA expression in super-enhancers controls transcription factor binding and consequently, regulates inflammatory gene expression. Interestingly, it also has been found that some lncRNAs called x-eRNA were targeted by the RNA exosome at super-enhancers ([@b47-molce-40-3-169]). Since eRNAs generate complexes with single-stranded DNA for protection from genomic instability by the rapid degradation activity of the RNA exosome complex, it could be suggested that super-enhancers might be connected with their target genes through RNA exosome-mediated transcription regulation. However, it is unclear whether the mechanism is dependent on direct RNA-protein complex at enhancer-promoter interaction yet.

THE ROLE OF SUPER-ENHANCER AND eRNA IN CANCER DEVELOPMENT
=========================================================

It is important to identify cancer-related epigenetic regulators and their functions to understand cancer pathogenesis. Oncogenes were shown to be regulated by super-enhancers ([@b6-molce-40-3-169]; [@b39-molce-40-3-169]; [@b50-molce-40-3-169]), and aberrant regulation of eRNA is closely related to tumorigenesis ([@b34-molce-40-3-169]; [@b60-molce-40-3-169]). Herein, recent discoveries of aberrant super-enhancers and eRNAs in various cancer types will be discussed ([Table 1](#t1-molce-40-3-169){ref-type="table"}).

Cancer-related super-enhancers
------------------------------

Cancer-related super-enhancers were found in various cancers such as colorectal cancer, small cell lung cancer, T cell acute lymphoblastic leukemia, and acute myeloid leukemia ([@b8-molce-40-3-169]; [@b20-molce-40-3-169]; [@b40-molce-40-3-169]; [@b48-molce-40-3-169]). Among the many cancer-related super-enhancers, those related to the *MYC* proto-oncogene and frequently hyperactivated in many cancer types ([@b10-molce-40-3-169]; [@b11-molce-40-3-169]; [@b12-molce-40-3-169]; [@b22-molce-40-3-169]; [@b57-molce-40-3-169]) have been well-defined ([@b2-molce-40-3-169]; [@b17-molce-40-3-169]; [@b37-molce-40-3-169]; [@b63-molce-40-3-169]). Interestingly, although super-enhancers at the *MYC* locus are common in most cancers, super-enhancers at this region undergo a different regulatory mechanism depending on the cancer type ([Fig. 2A](#f2-molce-40-3-169){ref-type="fig"}) ([@b8-molce-40-3-169]; [@b20-molce-40-3-169]). In the colorectal cancer cell line HCT-116, the super-enhancer region co-occupied with TCF4, and H3K27ac was observed at the *c-MYC* oncogene locus ([Fig. 2A](#f2-molce-40-3-169){ref-type="fig"}) ([@b20-molce-40-3-169]), which is a target of Wnt signaling ([@b68-molce-40-3-169]). This resulted in significantly higher expression of *c-MYC* in colorectal cancer cells, suggesting that this super-enhancer controls the oncogenic pathway ([@b20-molce-40-3-169]). Moreover, [@b18-molce-40-3-169] detected aberrant DNA methylation patterns on super-enhancers in HCT-116 cells, specifically, hypomethylation at super-enhancers regions of the *MYC* ([Fig. 2A](#f2-molce-40-3-169){ref-type="fig"}) and ring finger protein 43 (*RNF43)* oncogenes. Enrichment of forkhead box Q1 (FOXQ1) transcription factor binding sites was detected in hypomethylated super-enhancer regions of *MYC* ([Fig. 2A](#f2-molce-40-3-169){ref-type="fig"}) and *RNF43*, demonstrating that hypomethylated regions at colorectal cancer-specific super-enhancers are abundantly occupied by oncogenic transcription factors ([@b18-molce-40-3-169]). Christensen et al. identified specific super-enhancers in the small cell lung cancer (SCLC) cell lines NCI-H69, GLC16, and NCI-H82 ([@b8-molce-40-3-169]). Consistent with the results of a previous study suggesting differential gene expression profiles between 'classical' NCI-H69 and GLC16, and 'variant' NCI-H82 SCLC cell lines ([@b46-molce-40-3-169]), the classical cell lines showed similar super-enhancer associated gene profiles, whereas the variant cell line showed a different profile from that of the classical cell lines. Moreover, the existence of specific super-enhancers regulated independently by different SCLC cancer cell types has been elucidated at the region of the *MYC* gene family ([Fig. 2A](#f2-molce-40-3-169){ref-type="fig"}) ([@b8-molce-40-3-169]). These studies suggest that enhancer identification in SCLC models is important to understand SCLC pathogenesis and the specific characteristics of the disease.

The transcriptional regulatory mechanism of the *TAL1* oncogene was identified in T cell acute lymphoblastic leukemia (T-ALL) ([@b40-molce-40-3-169]). ChIP-seq analysis of H3K27ac indicated H3K27ac enrichment upstream of the transcription start site of the *TAL1* gene in Jurkat T-ALL cells ([Fig. 2B](#f2-molce-40-3-169){ref-type="fig"}). Additionally, this region possessed a heterozygous 12-bp insertion that introduced a *de novo* myeloblastosis oncogene (MYB) transcription factor binding motif, which recruited MYB and H3K27 acetylase-binding CREB-binding protein (CBP), increasing *TAL1* expression ([@b40-molce-40-3-169]) ([Fig. 2B](#f2-molce-40-3-169){ref-type="fig"}). Interestingly, deletion of an inserted mutation of the *TAL1* enhancer reduced endogenous *TAL1* expression levels through the collapse of the *TAL1* super-enhancer in Jurkat cells ([@b40-molce-40-3-169]), indicating that epigenetic regulators, including super-enhancers, act as master regulators to mediate gene expression. Taken together, these results suggest that intergenic mutations of noncoding elements create binding sites for master regulators and generate oncogenic super-enhancers in T-ALL cells, and identification of the mechanism of aberrant super-enhancer formation would provide insight for studies of novel therapeutic strategies in cancer ([@b40-molce-40-3-169]).

Pelish et al. identified mediator-associated cyclin-dependent kinase 8 (CDK8) as a negative regulator of super-enhancer associated transcription in acute myeloid leukemia (AML) cells ([@b48-molce-40-3-169]). ChIP-seq binding profiles at putative enhancer elements of CCAAT/enhancer binding protein, alpha (CEBPA) showed that CDK8 most closely related to MED1, followed by BRD4 and H3K27ac ([@b48-molce-40-3-169]). Furthermore, treatment with cortistatin A (CA), which inhibits mediator kinases including CDK8, increased the expression of tumor suppressor genes regulated by super-enhancers and inhibited AML progression in a xenograft model*,* suggesting that mediator-associated kinases can act as negative regulators of genes regulated by super-enhancers ([@b48-molce-40-3-169]).

Cancer-related enhancer RNAs
----------------------------

eRNAs are transcribed from enhancer regions, but their role in regulating enhancer activity remains unknown. [@b34-molce-40-3-169] performed global run-on sequencing (GRO-seq) in 17β-estradiol (E2)-treated human breast cancer cell line. They identified that E2-associated enhancers induced eRNA transcription from enhancers adjacent to E2-activated genes, and that knockdown of *FOXC1*, trefoil factor 1 (*TFF1*), or carbonic anhydrase 12 (*CA12*) eRNA reduced transcription of the adjacent coding genes but not of coding genes located distally to the corresponding enhancers ([@b34-molce-40-3-169]). Moreover, they provided evidence that E2-induced eRNA enhanced the strength of specific enhancer-promoter looping ([Fig. 2C](#f2-molce-40-3-169){ref-type="fig"}) ([@b34-molce-40-3-169]), demonstrating the important role of eRNA in controlling ligand-dependent target gene transcription and enhancer activity. Another group studied estrogen-mediated eRNAs at estrogen receptor (ESR1) binding sites (ERBSs) by novel computational methods, and found that eRNA transcription from ERBSs strongly correlated with promoter-enhancer looping in the target gene ([@b14-molce-40-3-169]). However, Hah et al. showed that inhibition of E2-induced eRNA production did not affect ESR1 enhancer assembly at ERBSs, despite the existence of a positive correlation between eRNA production and enhancer activity, suggesting that eRNA in MCF-7 cells is produced after active chromatin loop formation ([@b14-molce-40-3-169]; [@b29-molce-40-3-169]).

eRNA transcription in human breast cancer is induced not only by estrogen but also by nutlin-3a, an activator of p53 ([@b33-molce-40-3-169]). [@b33-molce-40-3-169] performed GRO-seq in MCF-7 cells treated with nutlin-3a to identify p53-regulated eRNAs and their role in p53-regulated enhancer activation. They discovered that lncRNA activator of enhancer domains (LED) is a p53-induced target, which binds to p53-regulated enhancer regions, inducing transcription of eRNA, such as *P21*, *TOB1*, *PRKAG2*, and *SUFU* ([@b33-molce-40-3-169]). Interestingly, a hypermethylated promoter region in LED was observed in human tumors, indicating that LED silencing is involved in cancer pathogenesis ([@b33-molce-40-3-169]).

Increased androgen receptor (AR) expression is critical for castration-resistant prostate cancer (CRPC) progression ([@b62-molce-40-3-169]). Therefore, it is important to elucidate the AR regulatory mechanism. [@b69-molce-40-3-169] identified a group of AR-regulated enhancer RNAs (AR-eRNAs) in CRPC cells, including the *PSA* eRNA, which was increased in CRPC, could bind to CYCLIN T1 and activate the P-TEFb complex, leading to increased Pol II-Ser2 phosphorylation (Polll-Ser2p) at both *cis* and *trans* targets. Furthermore, they demonstrated that *PSA* eRNA knockdown reduced CRPC cell growth, suggesting that eRNA may be a potential therapeutic target in CRPC ([@b69-molce-40-3-169]). The same research group has also reported that enzalutamide, a competitive AR inhibitor, altered AR-eRNA production in CRPC cells ([@b69-molce-40-3-169]). They identified differentially regulated AR-eRNAs in cells sensitive or resistant to enzalutamide, and revealed that *FTO*, *LUZP2*, *MARC1*, and *NCAM2* regulation may be related to enzalutamide resistance ([@b69-molce-40-3-169]). These results suggest that profiling eRNA alterations is a useful approach to understand the role of eRNA in enzalutamide resistance and to identify novel therapeutic targets for curing CRPC.

POTENTIAL THERAPEUTIC VALUE OF TARGETING SUPER-ENHANCERS OR eRNAS
=================================================================

As described above, dysregulated super-enhancers and eR-NAs are closely related to cancer development, hence, the therapeutic effects of targeting aberrant super-enhancers or eRNAs have been studied ([Table 2](#t2-molce-40-3-169){ref-type="table"}). Yokoyama et al. provided evidence suggesting that epigenetic regulators may be used as therapeutic targets in epithelial ovarian cancer (EOC) stem-like cells (CSCs) characterized by increased aldehyde dehydrogenase (ALDH) activity ([@b31-molce-40-3-169]; [@b59-molce-40-3-169]; [@b67-molce-40-3-169]). Because increased ALDH activity enhances stem-related gene expression and chemotherapy resistance in EOC ([@b31-molce-40-3-169]), therapeutic strategies targeting ALDH are important. Yokoyama et al. showed that the bromodomain and extraterminal (BET) inhibitor JQ1 suppressed *ALDH1A1* expression by influencing the BRD4-regulated super-enhancer and its associated eRNA ([@b67-molce-40-3-169]). Furthermore, combination treatment with JQ1 and cisplatin reduced tumor size, implying that regulating super-enhancer or eRNAs can be a future therapeutic strategy against ovarian cancer.

[@b24-molce-40-3-169] found that the known small-molecule specific CDK7 inhibitor THZ1 is a potent drug against oesophageal squamous cell carcinoma (OSCC). THZ1 injection reduced OSCC tumor weight and distal OCSS cell metastasis to the lungs ([@b24-molce-40-3-169]). Interestingly, treatment with low THZ1 doses decreased the levels of oncogenic transcripts, such as runt related transcription factor 1 (*RUNX1*), yes-associated protein 1 (*YAP1*), DnaJ heat shock protein family member B1 (*DNAJB1*), sterol regulatory element binding transcription factor 2 (*SREBF2*), and p21 activated kinase 4 (*PAK4*), which were associated with super-enhancers ([@b24-molce-40-3-169]). Indeed, *YAP1*, *SREBF2*, and *PAK4* were highly expressed in OSCC ([@b24-molce-40-3-169]). Moreover, Jiang et al. identified that administration of a novel PAK4 inhibitor effectively suppressed tumor growth in OSCC xenograft models ([@b24-molce-40-3-169]), demonstrating the merit of targeting super-enhancer-associated oncogenic transcripts for anti-OSCC treatment ([@b24-molce-40-3-169]).

CONCLUSIONS
===========

Despite massive efforts to study the function of enhancers, our overall understanding of how enhancers regulate tissue-specific gene expression was limited. The development of high-throughput sequencing technologies allowed the identification of complete transcription factor landscapes and histone modification marks in the whole genome. Comparative analysis between various tissues can lead to a comprehensive understanding of enhancers as master regulators during development. Numerous ChIP-seq data, describing enhancer epigenetic features in a tissue-specific manner, suggest that super-enhancers are involved in tissue-specific gene regulation. Functional studies through CRISPR/Cas9 revealed that individual enhancer elements in super-enhancers have unique functions. The next question to be considered is which elements are required to maintain the unique functions of enhancers, and further research is required to show whether enhancer functions are determined by the DNA sequence itself or the structure of the super-enhancer unit. Enhancers recruit transcription factors and mediators, but this might not be sufficient to enhance target gene expression. Many enhancers are co-occupied by RNA Pol II, leading to eRNA transcription. eRNA plays a role in enhancing target gene expression through the formation of enhancer-promoter looping. The mechanisms underlying eRNA function are not yet clear, but aberrant eRNAs have been identified during tumorigenesis, suggesting that epi-genetic regulators could be potential therapeutic targets.
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Histone modifications to identify active enhancers marked with high H3K27ac, high H3K4me1, and low/no H3K4me3. Super-enhancers are characterized by multiple enhancers co-occupied with lineage-specific transcription factors within tens of kilobases covered with extended H3K27ac. eRNAs are bi-directionally transcribed at enhancers and involved in promoter-enhancer interactions by binding with cohesin.](molce-40-3-169f1){#f1-molce-40-3-169}
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(A) Enrichment of super-enhancer associated with the *MYC* gene family in colorectal cancer and small cell lung cancer cell lines (B) *TAL1* super-enhancer in T cell acute lymphoblastic leukemia cell lines (C) Stabilization of E~2~/ERα/eRNA-induced enhancer-promoter looping in breast cancer cell lines.](molce-40-3-169f2){#f2-molce-40-3-169}

###### 

Super-enhancers and enhancer RNAs in cancer

  Cancer type                            Sample                                                 Super-enhancer associated genes          References
  -------------------------------------- ------------------------------------------------------ ---------------------------------------- -----------------------
  Colorectal cancer                      HCT-116                                                *C-MYC*                                  [@b20-molce-40-3-169]
                                         *RNF43*                                                [@b18-molce-40-3-169]                    
  Small cell lung cancer                 NCI-H69                                                *MYCN, INSM1, SOX2, NFIB, SOX4, ASCL1*   [@b8-molce-40-3-169]
  GLC16                                  *CSMD1, NFIB, INSM1, SOX2, MYC, SOX4, ASCL1*                                                    
  NCI-H82                                *MYC, OTX2, BCL-XL, NEUROG1, NEUROD1*                                                           
  T cell acute lylmphoblastic leukemia   Jurkat                                                 *TAL1*                                   [@b40-molce-40-3-169]
  Acute myeloid leukemia                 MOLM-14                                                *CEBPA*                                  [@b48-molce-40-3-169]
                                                                                                                                         
  Cancer type                            Sample                                                 Enhancer RNAs                            References
                                                                                                                                         
  Breast cancer                          MCF-7                                                  (E2-induced eRNAs) *TFF1, FOXC1, CA12*   [@b34-molce-40-3-169]
                                         (p53-regulated eRNAs) *P21, TOB1, PRKAG2, SUFU*        [@b33-molce-40-3-169]                    
  Castration-resistant prostate cancer   LNCaP, C4-2                                            (AR-regulated eRNAs)                     [@b70-molce-40-3-169]
                                         *ARHGEF26, KLK15, HTR3A, TLE1, SLC16A7*                                                         
                                         (enzalutamide resistance) *FTO, LUZP2, MARC1, NCAM2*   [@b69-molce-40-3-169]                    

###### 

Therapeutic effect targeted by super-enhancers or eRNAs

  Cancer type                           Target                              inhibitor               *In vivo* effect                                                           References
  ------------------------------------- ----------------------------------- ----------------------- -------------------------------------------------------------------------- -----------------------
  Ovarian cancer                        ALDH                                BET inhibitor (JQ1)     Reduction of tumor size under combination treatment of JQ1 and cisplatin   [@b67-molce-40-3-169]
  Oesophageal squamous cell carcinoma   RUNX1, YAP1, DNAJB1, STEBF2, PAK4   CDK7 inhibitor (THZ1)   Reduction of OSCC tumor weight and distal OSCC cell metastasis             [@b24-molce-40-3-169]
